Reviewing the Evidence: Olive Oil's Cardiovascular Effects (Tarabanis 2023)

This 2023 narrative review, published in Nutrition, Metabolism & Cardiovascular Diseases, synthesizes the highest-quality evidence on olive oil and cardiovascular outcomes -- twelve prospective cohort studies, totaling more than 200,000 participants, plus one meta-analysis -- and then evaluates whether commercially available capsule-form olive oil supplements can realistically deliver the doses observed in those studies. According to PubMed (DOI), the lead author is Dr. Constantine Tarabanis, a cardiologist at NYU Langone Health and Olivea's medical advisor.

Why This Study Matters

Olivea's relationship with this review is direct and worth stating clearly. Dr. Tarabanis serves as Olivea's medical advisor, and the central question this review asks is the same question Olivea set out to answer: can a capsule-form supplement deliver the cardiovascular benefits that have been documented for olive oil in large prospective cohorts?

That question is not rhetorical. Most cohort studies of olive oil report intake in the range of 10 to 35 grams per day -- roughly one to two-and-a-half tablespoons. Commercial olive oil capsules typically deliver 1 to 1.25 grams per capsule. Reaching the doses associated with cardiovascular benefit through capsules alone would require 8 to 35 capsules per day, which is not practical. Dr. Tarabanis and his coauthors at NYU Grossman School of Medicine quantify this gap and propose a path forward: supplements designed around the active phenolic compounds rather than around bulk olive oil mass.

The review credentialed the underlying clinical question that Olivea's product architecture answers. It is included here both for its scientific content and as a transparent disclosure of the advisor relationship.

How It Was Designed

The authors searched the literature for high-quality evidence on cardiovascular and other health effects of olive oil, with explicit inclusion criteria. Prospective cohort studies needed sample sizes of at least 4,000 individuals to qualify -- a threshold that excluded smaller observational studies and concentrated the review on the most statistically robust evidence base. Twelve cohorts met that threshold, alongside one meta-analysis.

The included cohorts followed participants typically aged 55 and older, free of cardiovascular disease at baseline but at elevated risk, over follow-up periods of 4 to 10 years. Daily olive oil consumption in these cohorts ranged from 10 to 35 grams per day. Only the PREDIMED cohort consistently differentiated between extra virgin and other olive oil varieties -- a methodological limitation the review explicitly flags.

The authors then evaluated commercially available olive oil dietary supplements against this benchmark, focusing on dose feasibility, phenolic content reporting, and the compositional reporting necessary to link supplement intake to the underlying clinical evidence.

What They Found

Across the twelve large prospective cohorts and meta-analysis, the review's central findings are summarized below:

Finding	Detail	Implication
CVD incidence and mortality	Lower with greater olive oil intake	Consistent across cohorts
Stroke risk	Lower with greater olive oil intake	Consistent across cohorts
Typical cohort dose range	10-35 g/day	Roughly 1-2.5 tablespoons daily
Capsule supplement dose	1-1.25 g/capsule	Cannot match cohort doses by bulk
Compositional reporting	Largely absent	Phenolic content rarely disclosed
Type differentiation	Only PREDIMED specified EVOO	Most cohorts conflate varieties

Green indicates favorable findings; red indicates limitations the review identifies in current supplement formulations and cohort methodology.

Reading the Results

The review's argument groups into three layered observations worth understanding together.

The clinical evidence base is strong but generic. Across twelve large prospective cohorts, higher olive oil intake was consistently associated with lower cardiovascular disease incidence, lower cardiovascular mortality, and lower stroke risk. The signal is reproducible across populations and follow-up durations. What the cohorts do not consistently report is which kind of olive oil drove the benefit -- extra virgin, refined, or a mix. Only PREDIMED used a defined EVOO intervention. The other eleven cohorts allow the inference that olive oil intake matters but leave the specific composition unresolved.

The phenolic content matters but is rarely measured. The plausible mechanisms for cardiovascular benefit -- reduction of oxidized LDL, anti-inflammatory effects on endothelium, improvement in HDL function -- track most strongly with phenolic compounds, particularly hydroxytyrosol and oleuropein. The 2011 EFSA-authorized health claim for olive oil polyphenols specifically addresses protection of blood lipids from oxidative damage. Yet most cohorts did not measure phenolic content of consumed oil, and most commercial supplements do not report it.

The supplement gap is quantitative. At 1 to 1.25 grams of olive oil per capsule, matching the lower bound of cohort intake (10 g/day) requires 8 to 10 capsules daily. Matching the upper bound (35 g/day) requires 28 to 35 capsules daily. The review concludes that bulk olive oil capsule supplementation cannot practically deliver the cohort-observed doses. The implication: supplements concentrated around the bioactive phenolic compounds, rather than around olive oil mass, are the rational design.

What Didn't Change

This is a narrative review, not an interventional trial. It does not establish new clinical effects of olive oil. Its contribution is synthesis: organizing the existing cohort literature against a defined inclusion threshold and identifying methodological gaps in both the underlying evidence and the supplement category.

The review also stops short of recommending specific supplement formulations. It calls for pragmatic trials of supplements with varying phenolic content -- the kind of study that has begun to appear in the literature (such as the 2025 hydroxytyrosol RCT in overweight prediabetic adults) but is not yet abundant enough to support strong category-wide guidance.

Broader Context

This review sits between two strands of olive oil research: the large cohort literature that establishes the association between intake and cardiovascular outcomes (including the Guasch-Ferre 2022 Harvard analysis of 92,383 U.S. adults) and the mechanistic and small-trial literature on isolated polyphenols (including the 2025 hydroxytyrosol RCT, which used 15 mg/day in capsule form and demonstrated significant improvements across seven oxidative stress and inflammation biomarkers). The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day -- a dose readily achievable through targeted supplementation but variable across whole oils.

The Tarabanis review credentials the central design question of phenolic-concentrated supplementation: not a substitute for olive oil in the diet, but a way to deliver the bioactive compounds at doses consistent with both the EFSA threshold and the emerging interventional literature.

Related Research

Continue exploring olive oil and polyphenol science:

• PREDIMED Republished: Mediterranean Diet + EVOO Cut Major CV Events by 30%
• CORDIOPREV: 7 Years of Mediterranean Diet for Secondary CV Prevention
• High-Phenolic vs Low-Phenolic Olive Oil: Meta-Analysis of 26 RCTs

Source: View the original study on PubMed

Olivea's Dosage

This review identified the practical gap between cohort-observed olive oil intake (10-35 g/day) and what bulk olive oil capsules can deliver. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams, well within the cohort intake range. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving, addressing the review's call for phenolic-content-defined supplementation; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.